A study of patients infected with acute hepatitis C virus (HCV) infection found that women had higher rates of spontaneous viral clearance—undetectable levels of the virus without initiating drug therapy. Findings published in Hepatology, a journal of the American Association for the Study of Liver Diseases, indicate that the gene IL28B (rs12979860) and HCV genotype 1 are also independent predictors of spontaneous HCV clearance.
In 2011, there were 1,229 cases of acute HCV reported to the Centers for Disease Control and Infection (CDC), which represents a 44% increase over 2010. Medical evidence indicates that 25% of those with acute HCV spontaneously clear their infection. Previous prospective studies link female sex, immune responses, neutralizing antibodies and genetics to viral clearance.
"Knowledge of acute HCV clearance is limited given that patients are typically asymptomatic during the initial stages of infection and at-risk populations, such as people who inject drugs, are often marginalized," explains lead author Dr. Jason Grebely at The Kirby Institute, University of New South Wales in Australia. "Our research aims to advance understanding of time to and predictors of HCV clearance to improve early therapeutic intervention options."
Researchers used data from the InC3 Study—a collaboration of nine prospective studies from Australia, Canada, the Netherlands, and the U.S. funded by the National Institutes of Health and led by Professor Kimberly Page from the University of California San Francisco—which included participants with HCV and human immunodeficiency virus (HIV) who were recruited between 1985 and 2010. The present study included 632 individuals diagnosed with acute HCV with 35% of the group being female and 82% Caucasian. Roughly 96% of participants had injected drugs, 47% were infected with HCV genotype 1 and 5% were co-infected with HIV.
Results show that 173 of the 632 participants had spontaneously cleared the virus during follow-up. At one year post-infection, 25% had HCV clearance. The average time to clearance among those who cleared HCV was 16.5 weeks, with 34%, 67% and 83% demonstrating clearance at 3, 6 and 12 months, respectively.
"Our findings indicate that females, those with the IL28B gene, and those with HCV genotype 1 are independent predictors of spontaneous clearance of acute HCV," concludes Prof. Kimberly Page. "Further research is necessary to understand the effect of sex in controlling HCV infection."
This studiy is published in Hepatology. Media wishing to receive a PDF of this article may contact sciencenewsroom@wiley.com.
Full citation: "The Effects of Female Sex, Viral Genotype and Il28b Genotype on Spontaneous Clearance of Acute Hepatitis C Virus Infection." Jason Grebely, Kimberly Page, Rachel Sacks-Davis, Maarten Schim van der Loeff, Thomas M. Rice, Julie Bruneau, Meghan D. Morris, Behzad Hajarizadeh, Janaki Amin, Andrea L. Cox, Arthur Y. Kim, Barbara H. McGovern, Janke Schinkel, Jacob George, Naglaa H. Shoukry, Georg M. Lauer, Lisa Maher, Andrew R. Lloyd, Margaret Hellard, Gregory J. Dore and Maria Prins on behalf of the InC3 Study Group. Hepatology; (DOI: 10.1002/hep.26639); Published Online: August 2, 2013.
URL: http://doi.wiley.com/10.1002/hep.26639
Author Contact: Media wishing to speak with Dr. Jason Grebely may contact Laurie Legere at the Kirby Institute: llegere@kirby.unsw.edu.au or at +61 413 476 647. Media wishing to speak with Dr. Kimberly Page may contact Jeff Sheehy at the University of California San Francisco jsheehy@ari.ucsf.edu or at +1 415-845-1132.
About the Journal
Hepatology is the premier publication in the field of liver disease, publishing original, peer-reviewed articles concerning all aspects of liver structure, function and disease. Each month, the distinguished Editorial Board monitors and selects only the best articles on subjects such as immunology, chronic hepatitis, viral hepatitis, cirrhosis, genetic and metabolic liver diseases and their complications, liver cancer, and drug metabolism. Hepatology is published on is published by Wiley on behalf of the American Association for the Study of Liver Diseases (AASLD). For more information, please visit http://wileyonlinelibrary.com/journal/hep.
About Wiley
Wiley is a global provider of content-enabled solutions that improve outcomes in research, education, and professional practice. Our core businesses produce scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising; professional books, subscription products, certification and training services and online applications; and education content and services including integrated online teaching and learning resources for undergraduate and graduate students and lifelong learners.
Founded in 1807, John Wiley & Sons, Inc. (NYSE: JWa, JWb), has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: Literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace. Wiley's global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company's website can be accessed at http://www.wiley.com.
Journal
Hepatology